Out of stock sold out
Biotech

After Lilly-Kelonia deal, are any in vivo biotechs left to buy?

Pitchbook’s Ben Zercher told Fierce he expects in vivo CAR-T dealmaking to slow due to a shortage of viable acquisition targets.
Will Maddox Apr 24, 2026 9:30am
A collection of the fungus among us

Compass, Usona and Transcend score priority vouchers amid psychedelic push

Apr 24, 2026 3:51pm
3 bioprocessing trendsand the critical enabler thats quietly driving them

3 bioprocessing trends—and the critical enabler that’s quietly driving them

Brought to you by Savillex
Lung

Avalyn aims for $182M IPO to fund ph. 3 trials of lung drugs

Apr 24, 2026 7:08am
Yu Lu-Fierce Biotechjpg

How WuXi AppTec’s Integrated Platform Is Helping Therapies Move Faster from Discovery to Patients

Brought to you by WuXi AppTec
computer and clinical science AI data

WCG acquires The Contract Network to streamline clinical trials

Apr 24, 2026 1:38pm
More News

Helus CEO out after two months—Chutes & Ladders

Apr 24, 2026 8:30am
Fierce Pharma

Regeneron ushers in new era with inaugural gene therapy approval

Apr 23, 2026 3:22pm
Fierce Pharma

Roche exec: Giredestrant may become company’s largest product

Apr 23, 2026 2:52pm

Pfizer cans work on next-gen conjugate in cancer patients

Apr 23, 2026 11:20am